PHAT
Phathom Pharmaceuticals, Inc.
$12.16
-0.57%
2026-05-08
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Key Fundamentals
Forward P/E
8.27
EPS (TTM)
$-2.09
Revenue Growth (YoY)
104.4%
Profit Margin
-76.8%
Beta
0.57
Market Cap
$967.0M
Avg Volume (10D)
1.8M
Recent Breakout Signals
No recent breakout signals detected for PHAT.
Recent Price Range (60 Days)
60D High
$14.39
60D Low
$9.73
Avg Volume
1.2M
Latest Close
$12.16
Get breakout alerts for PHAT
Sign up for Breakout Scanner to receive daily notifications when PHAT triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Phathom Pharmaceuticals, Inc. (PHAT) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors PHAT daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. PHAT operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.